China's Jingke Health raises Series A for personalised wellness push
What's the deal? Beijing Jingke Health IndustryDealroom has a profile for this one. Try Dealroom →, a Chinese developer and retailer of health products, has closed a Series A round, the company announced in August 2026. The round was backed by Qilu Zhenxuan, Beijing Chunyu Capital, and Fanzhi Yunlian.
What's the endgame? Jingke Health focuses on three core categories: weight loss, women's blood and energy replenishment, and sugar-reduction regulation. It has built a full-chain system spanning research, quality control, and service, drawing on scientific resources and big-data technology.
Why now? The company is targeting persistent pain points in China's broader health industry — product sameness, weak consumer trust, limited personalisation, and poor integration between online and offline channels.
The signal: The round reflects investor appetite for wellness startups betting on data-driven personalisation to stand out in a crowded, commoditised market.
Image credit: Generated with Gemini
